Panel
JW
James Whitaker
High · 5854M · DOB 9 Jul 1972 · MRN RN-19022
Day 12 post NSTEMI with DES to the mid-LAD. Residual risk is driven by smoking, LDL not yet at target, and dual antiplatelet therapy.
Post-ACS pathway
Allergies: None known
For full active treatment
Continued smoking after ACS
Single largest modifiable residual risk. Treat as an active diagnosis.
LDL 2.6 vs target <1.4
Early post-statin. If still high at 4–6 weeks, add ezetimibe.
Clinical parameters
LDL-C
2.6mmol/L
Ref <1.4
HbA1c
64mmol/mol
Ref <53
eGFR
78mL/min/1.73m²
Ref >60
Organ risk
Conditions
NSTEMI · DES to mid-LAD
Peak hs-TnI 1840
Type 2 diabetes
Hyperlipidaemia
Tobacco use
18 cigarettes/day
Obesity
BMI 32.4
Care team
Dr Lena Hart
Interventional cardiology
Dr Amara Okonkwo
Acute medicine
Sam Reid
Cardiac rehab
Next encounter
Cardiac rehabilitation intake
Sun 20 Sep · 15:00
Gym 2 · Sam Reid